Strategies and Systems-Level Interventions to Combat or Prevent Drug Counterfeiting: A Systematic Review of Evidence Beyond Effectiveness

Pharmaceutical Medicine

Volumn 30, Issue 5, 2016, Pages 263-276

  Fadlallah, Racha ^a   El Jardali, Fadi ^a,b   Annan, Farah ^a   Azzam, Hayat ^a   Akl, Elie A ^a,b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COUNTERFEIT DRUG;

AWARENESS; DRUG LEGISLATION; DRUG MARKETING; DRUG QUALITY; HEALTH CARE POLICY; HEALTH EDUCATION; HUMAN; LICENSING; PATENT; PRIORITY JOURNAL; PUNISHMENT; PURCHASING; REVIEW; SYSTEMATIC REVIEW;

EID: 84989911440     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/s40290-016-0156-4     Document Type: Review

References (48)

1. Buowari OV. Fake and counterfeit drug: a review. Afrimedic J. 2013;3(2):1–4.
2. Chika A, Bello SO, Jimoh AO, Umar MT. The menace of fake drugs: consequences, causes and possible solutions. Res J Med Sci. 2011;1(5):257–61.
3. Lancet. Fighting fake drugs: the role of WHO and pharma. Lancet. 2011;377(9778):1626.
4. Newton PN, Green MD, Fernandez FM, Day NP, White NJ. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006;6(9):602–13.
5. Mackey TK, Liang BA. Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Med. 2013;11:233.
6. World Health Organization. Report of the situation of counterfeit medicines bases on data collection tool: WHO Regions for Africa and Eastern Mediterranean. 2010. Available at http://www.who.int/medicines/services/expertcommittees/pharmprep/WHO-ACM-3IMPACTSurveyDataCollectionToolReport.pdf. Accessed 7 July 2016.
7. Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, et al. The primacy of public health considerations in defining poor quality medicines. PLoS Med. 2011;8(12):e1001139.
8. Clark F. Rise in online pharmacies sees counterfeit drugs go global. Lancet. 2015;386(10001):1327–8.
9. MacKey TK, Liang BA. Promoting online drug safety: using public-private partnerships to deter illicit online drug sales. J Commer Biotechnol. 2011;17(3):266–71.
10. Ratanawijitrasin S, Wondemagegnehu, E. Effective drug regulation. A multicountry study. Geneva: World Health Organization; 2002.
11. World Health Organization. International Medical Products Anti-Counterfeiting Taskforce. Counterfeit drugs kill! 2008. Available at: http://www.who.int/impact/FinalBrochureWHA2008a.pdf. Accessed 8 July 2016.
12. Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother. 2007;60(2):214–36.
13. Swaminath G. Faking it-I The menace of counterfeit drugs. Indian J Psychiatry. 2008;50(4):238–40.
14. Bigdeli M, Javadi D, Hoebert J, Laing R, Ranson K, Alliance for Health Policy and Systems Research Network of Researchers on Access to Medicines. Health policy and systems research in access to medicines: a prioritized agenda for low- and middle-income countries. Health Res Policy Syst. 2013;11:37.
15. El-Jardali F, Akl EA, Fadlallah R, Oliver S, Saleh N, El-Bawab L, et al. Interventions to combat or prevent drug counterfeiting: a systematic review. BMJ Open. 2015;5(3):e006290.
16. Edwards N, Barker PM. The importance of context in implementation research. J Acquir Immune Defic Syndr. 2014;67(Suppl 2):S157–62.
17. Lavis JN, Rottingen JA, Bosch-Capblanch X, Atun R, El-Jardali F, Gilson L, et al. Guidance for evidence-informed policies about health systems: linking guidance development to policy development. PLoS Med. 2012;9(3):e1001186.
18. Lewin S, Bosch-Capblanch X, Oliver S, Akl EA, Vist GE, Lavis JN, et al. Guidance for evidence-informed policies about health systems: assessing how much confidence to place in the research evidence. PLoS Med. 2012;9(3):e1001187.
19. Wells S, Bullen C. A near miss: the importance of context in a public health informatics project in a New Zealand case study. J Am Med Inform Assoc: JAMIA. 2008;15(5):701–4.
20. Anonymous. Supreme Court won’t review invasion-of-privacy case. AIDS Policy Law. 1996;11(21):10.
21. World Health Organization. Medicines: spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines. Fact sheet N 275. 2012. http://www.who.int/mediacentre/factsheets/fs275/en/. Accessed 7 Apr 2014.
22. Cuchet-Chosseler M, Bocoum O, Camara M, Abad B, Yamani E, Ordre des Pharmaciens du M. Results of a survey to evaluate the efficacy of a regional awareness campaign on counterfeit street medicines in Bamako, Mali and Nouakchott, Mauritania. Med Trop (Mars). 2011;71(2):152–6.
23. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689–703.
24. World Health Organization. Safety and security on the internet: challenges and advances in member states: based on the findings of the second global survey on eHealth. World Health Organization; 2011.
25. Abbasi A, Zahedi FM, Kaza S. Detecting fake medical web sites using recursive trust labeling. ACM trans Inf Syst. 2012;30(4):22–36.
26. Patel A, Norris P, Gauld R, Rades T. Drug quality in South Africa: perceptions of key players involved in medicines distribution. Int J Health Care Qual Assur. 2009;22(5):547–60.
27. Erhun WO, OO Babalola, MO Erhun. Drug regulation and control in Nigeria: the challenge of counterfeit drugs. J Health Popul Dev Ctries 2001;4(2): 23–4.
28. Jin S. The mobile laboratory: a new concept in medicines surveillance. WHO Drug Inf. 2009;23(1):16–20.
29. Risha PG, Msuya Z, Clark M, Johnson K, Ndomondo-Sigonda M, Layloff T. The use of minilabs to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience. Health Policy. 2008;87(2):217–22.
30. Lai CW, Chan WK. Legislations combating counterfeit drugs in Hong Kong. Hong Kong Med J. 2013;19(4):286–93.
31. Laven DL. Prescription drug wholesalers: drug distribution and the inspection process (a Florida perspective). J Pharm Pract. 2006;19(4):196–214.
32. Cohn J, von Schoen-Angerer T, Jambert E, Arreghini G, Childs M. When falsified medicines enter the supply chain: description of an incident in Kenya and lessons learned for rapid response. J Public Health Policy. 2013;34(1):22–30.
33. Simoens S. Analysis of drug authentication at the point of dispensing in Belgian and Greek community pharmacies. Ann Pharmacother. 2009;43(10):1701–6.
34. Astra Zeneca. EFPIA product verification project-joint final report. European Federation of Pharmaceutical Industries and Associations; 2010. p. 1–32.
35. Altunkan SM, Yasemin A, Aykac IT, Akpinar E. Turkish pharmaceuticals track and trace system. Health Inform Bioinform (HIBIT) 2012:24–30.
36. Labadie J. Forensic pharmacovigilance and substandard or counterfeit drugs. Int J Risk Saf Med. 2012;24(1):37–9.
37. Kabore L, Millet P, Fofana S, Berdai D, Adam C, Haramburu F. Pharmacovigilance systems in developing countries: an evaluative case study in Burkina Faso. Drug Saf. 2013;36(5):349–58.
38. Hartigan-Go K. Developing a pharmacovigilance system in the Philippines, a country of diverse culture and strong traditional medicine background. Toxicology. 2002;181–182:103–7.
39. Thomson J, Reid WS, Pullen H. Evaluation of counterfeit medicines available via the internet in Germany; implications for patient safety across the globe. J Sex Med. 2013;10:254–5.
40. Bate R, Tren R, Hess K, Mooney L, Porter K. Pilot study comparing technologies to test for substandard drugs in field settings. Afr J Pharm Pharmacol. 2009;3(4):165–70.
41. Growing threat from counterfeit medicines. Bull World Health Organ. 2010;88(4):247–8.
42. Williams A. Europe prepares to battle the counterfeiters. Pharm Technol Eur 2011;23:9–11.
43. Orizio G, Merla A, Schulz PJ, Gelatti U. Quality of online pharmacies and websites selling prescription drugs: a systematic review. J Med Internet Res. 2011;13(3):e74.
44. Fung CH, Woo HE, Asch SM. Controversies and legal issues of prescribing and dispensing medications using the Internet. Mayo Clin Proc. 2004;79(2):188–94.
45. Nielsen S, Barratt MJ. Prescription drug misuse: is technology friend or foe? Drug Alcohol Rev. 2009;28(1):81–6.
46. Department of Justice, Drug Enforcement Administration. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008; Final Rule. Fed Regist. 2009;74(64):15596–625.
47. Bate R, Hess K. Assessing website pharmacy drug quality: safer than you think? PLoS One. 2010;5(8):e12199.
48. Arrunada B. Quality safeguards and regulation of online pharmacies. Health Econ. 2004;13(4):329–44.